Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Harbour BioMed

Explore full profile

Biopharmaceutical company developing fully human antibody therapeutics for oncology and immunology

Cambridge, United StatesFounded 2016Biotech & Life Sciences
Valuation $1.27B Market cap · 2026
Revenue $202M Latest reported FY
EBITDA $95M Latest reported FY

About Harbour BioMed

Harbour BioMed is a global biopharmaceutical company focused on the discovery, development and commercialisation of novel antibody therapeutics for oncology, immunology and other therapeutic areas. Its proprietary Harbour Mice platform generates fully human monoclonal antibodies in two formats - H2L2 and heavy chain only (HCAb) - while the HCAb-based immune cell engagers (HBICE) are designed to deliver tumour-killing effects beyond what traditional combination therapies achieve.

The company combines internal R&D with strategic global collaborations, co-discovery and co-development partnerships, and selective acquisitions. Its platform has been licensed to biopharma partners including BeiGene and Innovent Biologics for fully human monoclonal antibody drug discovery.

Harbour BioMed operates globally, with a presence in the United States, Europe and China, and listed on the Hong Kong Stock Exchange (HKEX: 02142) in December 2020. The company continues to advance a pipeline of novel antibody therapeutics powered by its fully human antibody discovery engine.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2016
Headquarters
Cambridge, United States
Listing
IPO 2020
Sector
Biotech & Life Sciences
Power Law
Thoroughbred$100M+ revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

20 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A13 investors entered at this stage

  • Legend Capital
  • Advantech Capital
  • GIC
  • Cambridge University Endowment Fund (CUEF)
  • Vertex Holdings
  • Sovereign Wealth Funds
  • China Life Private Equity Investment
  • Zheshang Venture Capital
  • SK Group
  • Efung Capital
  • Zhejiang University Future Capital
  • Greater Bay Area Fund
  • JT New Century

Series B and later7 investors entered at this stage

  • Hudson Bay Capital Management
  • OrbiMed
  • ShenZhen GTJA Investment Group
  • Octagon Capital Partners
  • Sage Partners
  • Country Garden
  • AstraZeneca

Talent

Book a demo to see the people
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇨🇳 China76.5%
🇺🇸 United States19.8%
🇭🇰 Hong Kong1.2%
🇳🇱 Netherlands1.2%
🇬🇧 United Kingdom1.2%
5 countries shown
Web traffic by country
4.5K monthly visits
across markets
🇺🇸 United States66.7%
🇮🇳 India15.6%
🇨🇦 Canada13.3%
🇭🇰 Hong Kong4.4%
Top 4 markets shown

Patents

Estimated portfolio value
$48M

89 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Harbour BioMed on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Harbour BioMed on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles